HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 03:52:59 2024-04-19 pm EDT			5-day change	1st Jan Change
0.0025 ^USD	+66.67%		+66.67%	+92.31%

2023	Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	CI
2023	Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	CI

HTG Molecular Diagnostics : to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

September 21, 2021 at 08:01 am EDT

TUCSON, Ariz., Sept. 21, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will present in a fireside chat in Cantor Fitzgerald’s Virtual Global Healthcare Conference, being held September 27^th – 30^th, 2021.

Details for the fireside chat are below:

Date:	Thursday, September 30, 2021
Time:	2:00 PM Eastern / 11:00 AM Pacific
Webcast:	https://wsw.com/webcast/cantor12/htgm/2086560

Management will also be available for 1x1 meetings. If you would like to request a meeting, please email corporateaccess@cantor.com

About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptnome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

Contact:

Ashley Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com

Source: HTG Molecular Diagnostics, Inc.

2021 GlobeNewswire, Inc., source Press Releases

Latest news about HTG Molecular Diagnostics, Inc.

Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	23-08-25	CI
Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	23-08-16	CI
Trustee/Examiner Appointed Under Chapter 11 for HTG Molecular Diagnostics, Inc.	23-07-21	CI
HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index	23-06-14	CI
HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index	23-06-08	CI
Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer	23-06-05	CI
HTG Molecular Diagnostics, Inc. Filed for Bankruptcy	23-06-05	CI
HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization	23-05-18	CI
Top Premarket Gainers	23-05-17	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
HC Wainwright Adjusts Price Target on HTG Molecular Diagnostics to $6 From $15, Maintains Buy Rating	23-04-03	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
HTG Molecular Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Certain Warrants of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Restricted Stock Units of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Stock Options of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Common Stock of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event	23-01-09	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022	23-01-06	CI
China's Move to End COVID Quarantine for Inbound Travelers Sparks Premarket Gains for US Equities	22-12-27	MT
Top Premarket Gainers	22-12-27	MT
HTG Molecular Diagnostics to Begin Trading on Split-Adjusted Basis on Wednesday	22-12-20	MT
Transcript : HTG Molecular Diagnostics, Inc. - Special Call	22-12-13
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	22-12-12	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	22-12-12	MT

Chart HTG Molecular Diagnostics, Inc.

Duration

Period

More charts

Company Profile

HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
HTG MOLECULAR DIAGNOSTICS, INC.	+92.31%	3.32K
QUIDELORTHO CORPORATION	-46.92%	2.56B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+7.27%	1.66B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-15.17%	1.45B
BIOTAGE AB	+18.55%	1.2B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-15.69%	978M
CONTEC MEDICAL SYSTEMS CO.,LTD	-24.43%	875M
REVENIO GROUP OYJ	-9.20%	698M
VAREX IMAGING CORPORATION	-17.12%	687M
CELLAVISION AB	+5.90%	480M

Medical Diagnostic & Testing Equipment

HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Advanced Medical Equipment & Technology

HTG Molecular Diagnostics : to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Latest news about HTG Molecular Diagnostics, Inc.

Chart HTG Molecular Diagnostics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Medical Diagnostic & Testing Equipment